Compare with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES NATCO PHARMA ALKEM LABORATORIES/
NATCO PHARMA
 
P/E (TTM) x - 17.7 - View Chart
P/BV x 7.7 2.8 278.0% View Chart
Dividend Yield % 0.6 1.2 46.2%  

Financials

 ALKEM LABORATORIES   NATCO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
NATCO PHARMA
Mar-19
ALKEM LABORATORIES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589849 187.2%   
Low Rs1,232557 221.2%   
Sales per share (Unadj.) Rs417.5573.8 72.7%  
Earnings per share (Unadj.) Rs56.3176.0 32.0%  
Cash flow per share (Unadj.) Rs64.7198.2 32.6%  
Dividends per share (Unadj.) Rs12.706.25 203.2%  
Dividend yield (eoy) %0.90.9 101.3%  
Book value per share (Unadj.) Rs292.9842.7 34.8%  
Shares outstanding (eoy) m119.5736.50 327.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.41.2 275.8%   
Avg P/E ratio x25.14.0 627.3%  
P/CF ratio (eoy) x21.83.5 614.5%  
Price / Book Value ratio x4.80.8 577.2%  
Dividend payout %22.63.6 635.3%   
Avg Mkt Cap Rs m168,65325,660 657.3%   
No. of employees `000NA5.0 0.0%   
Total wages/salary Rs m9,1713,559 257.7%   
Avg. sales/employee Rs ThNM4,225.3-  
Avg. wages/employee Rs ThNM718.0-  
Avg. net profit/employee Rs ThNM1,295.9-  
INCOME DATA
Net Sales Rs m49,91520,945 238.3%  
Other income Rs m1,6451,302 126.4%   
Total revenues Rs m51,56122,247 231.8%   
Gross profit Rs m8,4827,948 106.7%  
Depreciation Rs m1,006810 124.2%   
Interest Rs m671193 347.5%   
Profit before tax Rs m8,4518,247 102.5%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,823 88.1%   
Profit after tax Rs m6,7316,424 104.8%  
Gross profit margin %17.037.9 44.8%  
Effective tax rate %19.022.1 86.0%   
Net profit margin %13.530.7 44.0%  
BALANCE SHEET DATA
Current assets Rs m27,06223,472 115.3%   
Current liabilities Rs m15,3247,287 210.3%   
Net working cap to sales %23.577.3 30.4%  
Current ratio x1.83.2 54.8%  
Inventory Days Days6792 72.1%  
Debtors Days Days4188 46.8%  
Net fixed assets Rs m12,61018,648 67.6%   
Share capital Rs m239365 65.5%   
"Free" reserves Rs m34,49034,525 99.9%   
Net worth Rs m35,02730,760 113.9%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38743,031 126.4%  
Interest coverage x13.643.7 31.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 188.6%   
Return on assets %13.615.4 88.5%  
Return on equity %19.220.9 92.0%  
Return on capital %24.927.4 90.6%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56311,536 56.9%   
Fx outflow Rs m3,0122,939 102.5%   
Net fx Rs m3,5528,597 41.3%   
CASH FLOW
From Operations Rs m7,2596,688 108.5%  
From Investments Rs m1,864-6,122 -30.5%  
From Financial Activity Rs m-9,273-509 1,821.7%  
Net Cashflow Rs m-15066 -227.3%  

Share Holding

Indian Promoters % 66.9 52.0 128.6%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 33.1 7.8 422.2%  
FIIs % 0.0 16.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 26.0 -  
Shareholders   68,381 25,395 269.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Apr 3, 2020 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS